Related Experiment Videos
Section IV: selective use of neoadjuvant therapy.
Jasleen Kukreja1, Michael T Jaklitsch
1Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Seminars in Thoracic and Cardiovascular Surgery
|July 3, 2003
Summary
Neoadjuvant chemoradiation therapy may improve outcomes for localized esophageal cancer. Selective use in high-risk patients, similar to non-small cell lung cancer (NSCLC), is advocated based on institutional data.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Esophageal cancer treatment algorithms are less established than lung cancer due to lower incidence.
- Single-modality treatments (radiation or chemotherapy) are insufficient for a reliable cure.
- Debate exists regarding neoadjuvant chemoradiation therapy plus surgery versus surgery alone.
Purpose of the Study:
- To advocate for the selective use of neoadjuvant chemoradiation therapy in localized esophageal cancer.
- To propose a treatment approach similar to stage IIIA (N2) non-small cell lung cancer (NSCLC).
- To support this approach using single-institution data.
Main Methods:
- Review and summarization of single-institution data.
- Analysis of treatment outcomes for localized esophageal cancer.
- Comparison of neoadjuvant chemoradiation therapy plus surgery versus surgery alone.
Main Results:
- Neoadjuvant chemoradiation therapy is suggested as beneficial for specific high-risk groups.
- The study highlights the importance of precise staging for treatment selection.
- Institutional data supports the selective application of this combined therapy.
Conclusions:
- Selective use of neoadjuvant chemoradiation therapy is recommended for localized esophageal cancer.
- Careful patient selection based on staging is crucial for optimizing treatment efficacy.
- This approach may offer an improved alternative to surgery alone for high-risk patients.